1
|
Methodology of Selecting the Optimal Receptor to Create an Electrochemical Immunosensor for Equine Arteritis Virus Protein Detection. CHEMOSENSORS 2021. [DOI: 10.3390/chemosensors9090265] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The study reports a methodology of selecting the optimal receptor to create an electrochemical immunosensor for equine arteritis virus (EAV) protein detection. The detection was based on antigen recognition by antibodies immobilized on gold electrodes. Modification steps were controlled by electrochemical impedance spectroscopy and cyclic voltammetry measurements. In order to obtain the impedance immunosensor with the best parameters, seven different receptors complementary to equine arteritis virus protein were used. In order to make the selection, a rapid screening test was carried out to check the sensor’s response to blank, extremely low and high concentrations of target EAV protein, and negative sample: M protein from Streptococcus equi and glycoprotein G from Equid alphaherpesvirus 1. F6 10G receptor showed the best performance.
Collapse
|
2
|
Shanmugham R, Thirumeni N, Rao VS, Pitta V, Kasthuri S, Singanallur NB, Lingala R, Mangamoori LN, Villuppanoor SA. Immunocapture enzyme-linked immunosorbent assay for assessment of in vitro potency of recombinant hepatitis B vaccines. CLINICAL AND VACCINE IMMUNOLOGY : CVI 2010; 17:1252-60. [PMID: 20592114 PMCID: PMC2916243 DOI: 10.1128/cvi.00192-10] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/12/2010] [Revised: 06/17/2010] [Accepted: 06/21/2010] [Indexed: 11/20/2022]
Abstract
Quantification of hepatitis B surface antigen (HBsAg) or relative in vitro potency in the final vaccines is a prerequisite for hepatitis B vaccine batch release. The commercial kit for automated analysis (AxSYM) is expensive, and an alternative is required for the estimation of HBsAg in hepatitis B vaccines. Mouse monoclonal antibodies (MAbs) specific for HBsAg were developed and characterized. One of the monoclonal antibodies (HBs06) was used in development of an immunocapture ELISA (IC-ELISA) as an unlabeled capture antibody and biotin-labeled detection antibody. The IC-ELISA was standardized and validated using experimental hepatitis B vaccine batches with various HBsAg concentrations per dose and commercial vaccines. The vaccine was treated with an alkaline solubilizer to desorb the HBsAg from Algel-adjuvanted vaccines before testing, and the sensitivity of the test was 5 ng/ml. A good correlation could be observed between the HBsAg estimates derived by both formats, except for the higher HBsAg concentration range, where the IC-ELISA format could estimate closer to the actual values than AxSYM. There was a significant correlation between the estimated relative potencies of the two methods. There was lack of correlation between the in vivo potency and the relative in vitro potency. However, the estimates of IC-ELISA were comparable to the in vivo values when compared with the estimates of AxSYM. The IC-ELISA can therefore be considered to be a reliable test for deriving in vitro relative potency and antigen concentration in vaccine batches for batch control and release.
Collapse
Affiliation(s)
- Rajalakshmi Shanmugham
- Research and Development Centre, Indian Immunologicals Limited, Rakshapuram, Gachibowli, Hyderabad 500032, India, Institute of Science and Technology, Jawaharlal Nehru Technological University, Kukkatpally, Hyderabad 500072, India
| | - Nagarajan Thirumeni
- Research and Development Centre, Indian Immunologicals Limited, Rakshapuram, Gachibowli, Hyderabad 500032, India, Institute of Science and Technology, Jawaharlal Nehru Technological University, Kukkatpally, Hyderabad 500072, India
| | - Varaprasada Sankarashetty Rao
- Research and Development Centre, Indian Immunologicals Limited, Rakshapuram, Gachibowli, Hyderabad 500032, India, Institute of Science and Technology, Jawaharlal Nehru Technological University, Kukkatpally, Hyderabad 500072, India
| | - Vidyasagar Pitta
- Research and Development Centre, Indian Immunologicals Limited, Rakshapuram, Gachibowli, Hyderabad 500032, India, Institute of Science and Technology, Jawaharlal Nehru Technological University, Kukkatpally, Hyderabad 500072, India
| | - Saranyarevathy Kasthuri
- Research and Development Centre, Indian Immunologicals Limited, Rakshapuram, Gachibowli, Hyderabad 500032, India, Institute of Science and Technology, Jawaharlal Nehru Technological University, Kukkatpally, Hyderabad 500072, India
| | - Nagendrakumar Balasubramanian Singanallur
- Research and Development Centre, Indian Immunologicals Limited, Rakshapuram, Gachibowli, Hyderabad 500032, India, Institute of Science and Technology, Jawaharlal Nehru Technological University, Kukkatpally, Hyderabad 500072, India
| | - Rajendra Lingala
- Research and Development Centre, Indian Immunologicals Limited, Rakshapuram, Gachibowli, Hyderabad 500032, India, Institute of Science and Technology, Jawaharlal Nehru Technological University, Kukkatpally, Hyderabad 500072, India
| | - Lakshmi Narsu Mangamoori
- Research and Development Centre, Indian Immunologicals Limited, Rakshapuram, Gachibowli, Hyderabad 500032, India, Institute of Science and Technology, Jawaharlal Nehru Technological University, Kukkatpally, Hyderabad 500072, India
| | - Srinivasan Alwar Villuppanoor
- Research and Development Centre, Indian Immunologicals Limited, Rakshapuram, Gachibowli, Hyderabad 500032, India, Institute of Science and Technology, Jawaharlal Nehru Technological University, Kukkatpally, Hyderabad 500072, India
| |
Collapse
|